Evidence map›Paper›PMID 33938620›Full record

ArticleEMBO molecular medicine2021

Identification of TAPBPL as a novel negative regulator of T-cell function.

Yujun Lin, Cheng Cui, Min Su, Lawrence K Silbart, Haiyan Liu, Jin Zhao, Lang He, Yuanmao Huang, Dexin Xu, Xiaodan Wei and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. L-type voltage-gated CaEMBO reports · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Yujun LinDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.ORCID 0000-0002-8937-1259
Cheng CuiDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Min SuDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Lawrence K SilbartDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Haiyan LiuDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Jin ZhaoDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Lang HeDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Yuanmao HuangDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Dexin XuDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Xiaodan WeiDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Qian DuPlant Biology Section, Cornell University, Ithaca, NY, USA.
Laijun LaiDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
University of Connecticut · USFujian Medical University · CNBinzhou Medical University · CNCornell University · US

Funding

Transplantation of ESC-derived thymic epithelial progenitors expressing autoantigen(s) ameliorating experimental autoimmune encephalomyelitisR01AI123131 · NIAID · UNIVERSITY OF CONNECTICUT STORRS · PI LAI, LAIJUN · 2016 to 2020
$1.9M
NIAID NIH HHS R01 AI123131
6 · The paper itself

Abstract

T cell stimulatory and inhibitory molecules are critical for the regulation of immune responses. In this study, we identify a novel T cell co-inhibitory molecule TAPBPL, whose amino acid sequence shares homology with known B7 family members. TAPBPL protein is expressed on resting and activated T cells, B cells, monocytes, and dendritic cells (DCs), as well as on some tumor tissues. The putative TAPBPL receptor is expressed on activated CD4 and CD8 T cells. A soluble recombinant human TAPBPL-IgG Fc (hTAPBPL-Ig) fusion protein inhibits the proliferation, activation, and cytokine production of both mouse and human T cells in vitro. In vivo administration of hTAPBPL-Ig protein attenuates experimental autoimmune encephalomyelitis (EAE) in mice. Furthermore, an anti-TAPBPL monoclonal antibody neutralizes the inhibitory activity of hTAPBPL-Ig on T cells, enhances antitumor immunity, and inhibits tumor growth in animal models. Our results suggest that therapeutic intervention of the TAPBPL inhibitory pathway may represent a new strategy to modulate T cell-mediated immunity for the treatment of cancer, infections, autoimmune diseases, and transplant rejection.

Indexed as

CD8-Positive T-LymphocytesEncephalomyelitis, Autoimmune, ExperimentalAmino Acid SequenceAnimalsB-LymphocytesLymphocyte ActivationMiceMonocytesautoimmune diseaseB7 familyTAPBPLT cellstumor immunity

Identifiers

PMID33938620
PMCPMC8103088
OpenAlexW3159440612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.